Uncategorized Archives - Page 10 of 87 - PsychedelicNewsWire (PNW)

FridayApr 08, 2022 9:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Strengthening Foothold in Multibillion-Dollar Mental Health Space

Recent study forecasts global mental health market to reach almost $538B by 2030 One in five people in the United States deals with mental illness, including depression, anxiety, PTSD and more Cybin is moving three drug candidates forward, targeting major depressive, alcohol use and anxiety disorders A recent market study reports that the global mental health market, which was valued at $383.31 billion in 2020, is estimated to reach $537.97 billion by 2030, growing at a compound annual growth rate of 3.5% from 2021 to 2030 (https://ibn.fm/J7hfJ). With three active drug programs targeting mental-health disorders, Cybin (NEO: CYBN) (NYSE American: CYBN)…

WednesdayApr 06, 2022 3:09 pm

How You Can Participate in a Psychedelic Clinical Trial

These last few years, clinical trials on the use of psychedelics such as MDMA, LSD or psilocybin as treatments for various mental health conditions have increased significantly. For clinical trials to run, however, participants are needed. At first glance, it may seem easy to enroll individuals for trials given that quite a number of people suffer from mental conditions such as depression and anxiety. However, for an individual to be enrolled into a clinical trial, they must meet the stipulated inclusion criteria in order to be eligible. Below are steps on how one can enroll in a psychedelic clinical trial.…

TuesdayApr 05, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Recruitment for Study Measuring Ketamine’s Psychedelic Effect

Cybin-sponsored study will use Kernel Flow, Kernel’s quantitative neuroimaging. Company hopes to learn more about impact ketamine has on brain activity, overall mental well-being. Study results may lead to future studies supporting CYBN’s mission to develop psychedelics into therapeutics. Cybin’s (NEO: CYBN) (NYSE American: CYBN) efforts to transform the mental-health treatment landscape have reached a key milestone: the company is actively recruiting participants for its upcoming feasibility study using Kernel Flow, Kernel’s quantitative neuroimaging technology (https://ibn.fm/9aSxc). “The feasibility study using Kernel Flow offers an opportunity for researchers and our study participants to quantifiably gather information on a psychedelic experience,” said Cybin…

TuesdayApr 05, 2022 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Leveraging Growth Across Multiple Markets Including Mental Health, Healthcare IT

Mydecine was founded in 2020 as a response to the lack of innovation addressing mental health treatment and the therapeutic possibilities represented by psychedelic compounds and other novel molecules The world is experiencing a shortage of mental health resources, while faced with an increase in mental health issues on the heels of the pandemic Mydecine is leveraging the psychedelic drugs market, the PTSD market, and healthcare IT markets – with potential growth across all avenues In the first year of the COVID-19 pandemic, the prevalence of anxiety and depression worldwide increased by 25%, according to a World Health Organization (“WHO”)…

MondayApr 04, 2022 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) CEO to Present at Three Upcoming Investor Conferences Spotlighting the Company’s Strategic Outlook for the Remainder of 2022

Delic Holdings Co-founder and CEO, Matt Stang, will take part in three upcoming conferences – the Scottdale Capital Event, the Planet MicroCap Showcase, and the H.C. Wainwright Annual Global Life Sciences Conference In presentations and one-on-one meetings, Stang will discuss Delic’s new revenue lines and strategic outlook for the remainder of the year During a recent interview on The Jesse Tee Show, Stang noted the company intends to scale its ketamine clinics as well as build infrastructure to accommodate expanded psychedelic healing The company hopes to utilize its expanded infrastructure to help destigmatize mental health conditions Delic Holdings (CSE: DELC)…

WednesdayMar 30, 2022 9:00 am

Silo Pharma Inc. (SILO) Is ‘One to Watch’

Silo recently extended its option with the University of Maryland, Baltimore to explore arthritogenic joint-homing peptides and their use in arthritis-inflamed joints In December 2021, the company announced the issuance of a patent relating to its University of Maryland, Baltimore licensed homing peptide for enhanced targeting of therapeutic agents to the central nervous system The company signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD Silo currently has under review four U.S.…

MondayMar 28, 2022 9:00 am

Delic Holdings Corp’s (CSE: DELC) (OTCQB: DELCF) Co-Founder and CEO Offers a Glimpse into the Company’s History and Future on The Jesse Tee Show

While appearing on The Jesse Tee Show, the company’s co-founder and CEO, Matt Stang, shared his professional background, Delic’s history, its growth, and its plans going forward Mr. Stang attributes its success to understanding where opportunities and people connect, how to make things win-win for all people, and giving customers value Founded in 2016, Delic Holdings Corp now has a market cap of $4.32 million as of March 2022 Delic Holdings (CSE: DELC) (OTCQB: DELCF) has been at the forefront of reframing the psychedelic conversation. It has also remained committed to bringing science-backed benefits of psychedelics to the health industry,…

MondayMar 28, 2022 9:00 am

Psychedelic Medicine Researcher Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Readies IND Application to Advance Drug Trials

Novel drug development company Mydecine Innovations Group is focusing on a medicinal pipeline for psychedelic drug candidates that have established some efficacy in treating mental illnesses — specifically addiction Mydecine is progressing in its clinical trial evaluation of its lead candidate, MYCO-001, and is finalizing an IND application with the FDA to begin patient dosing for its planned Phase 2 trials The company is targeting nicotine addiction in tobacco smokers Mydecine is also advancing its evaluation of other drug candidates with pending patents to enhance its existing products Medical-use psychedelic drug product developer Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF)…

FridayMar 25, 2022 9:00 am

Delic Holdings Corp (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Makes Psychedelic Treatment More Accessible with Opening of New Reno Clinic

Following the acquisition of KWC back in November 2021, Delic Holdings Corp set out to open additional state-of-the-art ketamine infusion treatment clinics over the course of 18 months The company has just announced the opening of its second clinic in Nevada in a move that will serve both local patients and those in larger California markets without access to affordable in-state providers Delic is still set to open more clinics over the course of the next 18 months in a move that seeks to expand access to reasonably priced treatments for various mental health conditions In November 2021, Delic Holdings…

ThursdayMar 24, 2022 9:15 am

Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Is a Leader in Psychedelic-Based Therapies; Recent Preclinical Research Shows Treatment Effective for MDD

Study shows that substantial antidepressant effects of psilocybin-based treatment, given with supportive psychotherapy, may last at least a year. Psilocybin could lead to significant, durable improvements in depression. Cybin is focused on improving overall mental health through psychedelic-based therapies. Johns Hopkins Medicine researchers have released a report noting that psilocybin treatment for major depression is effective for up to a year for many patients (https://ibn.fm/ZF8jH). That bodes well for Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company that is focused on revolutionizing mental health care, including major depressive disorder (“MDD”). “Previous studies by Johns Hopkins Medicine researchers…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Uncategorized